Value of Repetitive Transcranial Magnetic Stimulation of the Motor Cortex in the Management of Refractory Cancer Pain in Palliative Care: A Case Report

Nathalie Denis1, Jean Paul Nguyen2, Edwige de Chauvigny1, Gérard Dabouis1, Emmanuelle Kuhn1, Aurélie Lepeintre1, Sylvie Raoul1, Jean-Jacques Labat1, Jean-Pascal Lefaucheur3 and Julien Nizard1*

1Centre Fédératif Douleur-Soins de Support-Ethique Clinique; UIC 22 et Laboratoire de Thérapeutique (EA3826), Centre Hospitalier Universitaire, Nantes, France
2Service de Neurochirurgie, Pôle OTONN, Centre Hospitalier Universitaire, Nantes, France
3EA 4391 et Service de Physiologie-Explorations fonctionnelles, Faculté de médecine Henri Mondor, Créteil, France

Abstract
Terminal cancer patients often experience pain that is difficult to treat. High doses of analgesics may be insufficient to relieve pain or may induce unacceptable adverse effects, especially drowsiness. We report the first case of a patient in whom pelvic pain was markedly improved by a series of five sessions of Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex. Medical treatment was able to be significantly decreased, and the quality of the patient’s end of life was improved.

Keywords: Refractory pain; Cancer pain; Quality of life; Repetitive transcranial magnetic stimulation; rTMS

Introduction
A large proportion of cancer patients experience chronic pain [1]. Cancer pain may correspond to nociceptive pain generally relieved by the administration of opioid analgesics [2], neuropathic pain requiring the use of specific medications such as anticonvulsants or antidepressants [3,4], and often mixed pain. Pain can become difficult to control at the terminal phase of cancer due to the mixed nature of the pain and the need to administer high-dose drug combinations [5], often accompanied by drowsiness, which contributes to deterioration of the quality of the end of life [6]. We report the case of a patient whose pelvic pain was able to be controlled by 5 repetitive transcranial magnetic stimulation sessions. In particular, the marked reduction of analgesic medications, measured by the Medication Quantification Scale (MQS) [7] score, allowed return to a normal level of consciousness and allowed the patient to be married under acceptable conditions before her death, as she had wished.

Clinical Case Report
In August 2009, a patient of 23 years old had several episodes of haematochezia, leading to the discovery of adenocarcinoma of the rectum. Treatment consisted of radiotherapy and abdominopelvic resection in February 2010, followed by chemotherapy. She presented local disease progression despite this treatment with the discovery of peritoneal carcinomatosis in October 2011 with liver and lung metastases. The health status of the patient gradually deteriorated with increased abdominal and pelvic pain, which partly corresponded to nociceptive pain, due to compression by the tumor. This pain was initially treated by oral morphine at a daily dose of 40 mg, which was increased to 200 mg after 4 months. She also had neuropathic pain (DN4 score: 7/11 [8]), as a consequence of surgery and radiotherapy. This pain was treated by a combination of pregabalin (300 mg daily) and intravenous amitriptyline (gradually increased to a dosage of 100 mg daily). The patient continued to experience pain despite this treatment with a Numerical Rating Scale (NRS) varying between 8 and 10/10. She also suffered from drowsiness and intellectual slowing that fluctuated with the dose of drugs and that confined her to bed. She was also taking antidepressant and anxiolytic treatment in the context of psychiatric follow-up and received regular psychological support. In this context, she was admitted to the Palliative Care Unit of our Federative Pain-Palliative and Supportive Care Centre in December 2012. During her brief periods of lucidity, this patient informed us about her desire to organize a wedding ceremony. She wanted a wedding ceremony taking place under the usual conditions, including a civil ceremony at the town hall and a religious ceremony. This project appeared to be impossible unless the drug doses could be decreased in order to limit their adverse effects. Initiation of NMDA receptor antagonist (ketamine) treatment failed to decrease pain or the doses of major opioids. Intrathecal administration of morphine after implantation of an injection port was also ineffective and the procedure had to be stopped after 10 days. Introduction of midazolam was minimally effective and accentuated the patient’s drowsiness. The MQS score used to quantify therapeutic doses was then 126 (Figure 1).

At that time, a therapeutic trial of motor cortex stimulation by rTMS was proposed, since we already had good results in two cases of refractory pelvic and perineal pain [9]. The patient received stimulation of the right motor cortex, in the zone corresponding to the representation of the perineal region [10] for 20 minutes with the following parameters: 20 trains of 10 seconds at 10 Hz to 80% of the resting motor threshold with an inter-train interval of 50 seconds (2000 stimuli). The patient experienced a marked improvement of her pain over the days following the first rTMS session. Medical treatment was able to be rapidly decreased by about 50% (MQS score decreased to 96 and then to 56) (Figure 1), which restored an almost normal level of consciousness and lucidity throughout the day. She was also able to resume walking. In parallel, we observed a reduction of her anxiety and depression symptoms. However, antidepressant treatment was maintained, but the doses of benzodiazepines were able to be reduced by one half. Four other rTMS sessions were performed to maintain...
The relevance of this target was confirmed by many studies that have been performed in the past decades. The rare adverse effects are usually only minor [16,17]. The target for the treatment of chronic pain is the precentral motor cortex, rather than somatosensory cortical areas. It may first appear surprising, but the relevance of this target was confirmed by many studies that have provided convincing evidences for the efficacy and mechanisms of action of invasive and noninvasive motor cortex stimulation [16-19]. It has also been regularly observed that, even in the case of bilateral or midline pain, as in the present case, stimulation on only one side could be sufficient [9]. Normally, the rTMS target used to treat depression is the dorsolateral prefrontal cortex [20]. A concomitant improvement of pain and depression, as the affective component of pain, was already observed in chronic pain patients treated by motor cortex stimulation [21]. This combined effect could be particularly useful in the context of the end of life. In the present case, a series of five rTMS sessions in a week allowed a significant reduction of analgesics that led the patient to recover a sufficient level of consciousness, lucidity and motivation to complete a complex project at the end of life such as the organisation of her wedding.

**Conclusion**

In the context of palliative care of cancer pain patients at the end of life, motor cortex rTMS can be used as an adjuvant therapy likely to improve various components of pain, including the emotional-affective components such as depression. In addition, by reducing the doses of analgesics, rTMS decreases the severity of their adverse effects, which can lead to a marked improvement in the quality of life of the patient.

**References**


